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Abstract
Background: Pneumococcal conjugate vaccines (PCVs) are in the process of implementation in Latin America.
Experience in developed countries has shown that they reduce the incidence of invasive and non-invasive disease.
However, there is evidence that the introduction of PCVs in universal mass vaccination programs, combined with
inappropriate and extensive use of antibiotics, could be associated to changes in non-PCV serotypes, including
serotype 19A. We conducted a systematic review to determine the distribution of serotype 19A, burden of
pneumococcal disease and antibiotic resistance in the region.
Methods: We performed a systematic review of serotype 19A data from observational and randomized clinical
studies in the region, conducted between 1990 and 2010, for children under 6 years. Pooled prevalence estimates
from surveillance activities with confidence intervals were calculated.
Results: We included 100 studies in 22 countries and extracted data from 63. These data reported 19733 serotyped
invasive pneumococcal isolates, 3.8% of which were serotype 19A. Serotype 19A isolates were responsible for 2.4%
acute otitis media episodes, and accounted for 4.1% and 4.4% of 4,380 nasopharyngeal isolates from healthy
children and in hospital-based/sick children, respectively. This serotype was stable over the twenty years of
surveillance in the region. A total of 53.7% Spn19A isolates from meningitis cases and only 14% from non
meningitis were resistant to penicillin.
Conclusions: Before widespread PCV implementation in this region, serotype 19A was responsible for a relatively
small number of pneumococcal disease cases. With increased use of PCVs and a greater number of serotypes
included, monitoring S. pneumoniae serotype distribution will be essential for understanding the epidemiology of
pneumococcal disease.
Keywords: Streptococcus pneumoniae serotype 19A, Latin American and the Caribbean, Resistance to penicillin,
Conjugate vaccines, Serotype replacement
Background
Streptococcus pneumoniae causes invasive pneumococcal
disease (IPD), which is often life-threatening in children
less than 2 years old, adults older than 65 years old and
immunocompromised individuals [1]. Pneumococcus is
also the most common cause of bacterial acute otitis
media (AOM) and sinusitis in children [1-3].
The most important virulence factor in pneumococcus
is the polysaccharide capsule, which forms the basis for
serotyping and vaccine formulation; 93 distinct serotypes
have been identified (with the recent inclusion of sero-
types 6C, 6D and 11E) [3-6]. Worldwide, 20 serotypes
account for more than 80% of IPD, although their preva-
lence varies by region [4]. A small number of pneumo-
coccal resistant clones, serotypes 14, 23F, 6B, 6A, 9V,
15A, 19F and 19A, have spread and display particularly
high rates of penicillin non susceptibility (PNSP) as well
as multiresistance profiles (MDR) [7].
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Since the introduction of pneumococcal conjugate
vaccines (PCVs), numerous studies have been published
on their safety, immunogenicity and efficacy, in particu-
lar for the heptavalent vaccine (PCV7), introduced in the
USA in 2000 [8,9]. Studies conducted after PCV7 intro-
duction, have shown dramatic and sustained decreases
in vaccine type (VT) IPD rates, carriage and herd effects
[10-13]. These positive findings were followed by reports
of IPD caused by non vaccine types (NVT) S. pneumo-
niae PNSP and MDR [14-18]. NVT have also been
described as agents of non invasive disease [15] and
nasopharyngeal carriage [12]. Data from both North
America and Europe have shown S. pneumoniae sero-
type 19A (Spn19A) to be the most prevalent serotype,
associated with increasing rates of MDR [19]. Conse-
quently, attention has focused on Spn19A, its prevalence
and the numerous factors leading to this increase, and
how best to control its impact [20-22].
This review summarizes the available published and
unpublished Latin American and Caribbean (LAC) data
from 1990 through 2010 describing the prevalence and
burden of Spn19A in children less than 6 years. For
comparison, we also analyzed the data for the most
prevalent serotypes in this region [23].
Methods
We searched for data collected between January 1990 and
July 2010 following PRISMA guidelines. Using both refined
search strategies and broad spectrum, low specificity,
searches (i.e. “Streptococcus pneumoniae” OR “pneumococ-
cus” anywhere in the text), we reviewed all references on S.
pneumoniae that were geographically linked to LAC coun-
tries, with no language restrictions; the targeted age group
was children 6 years-old or younger. We searched the fol-
lowing databases: Medline (PubMed), Embase, Latin Ameri-
can and Caribbean Health Sciences Information (LILACS),
Scientific Electronic Library on Line (SciELo) and SCOPUS.
Search terms used are shown in Additional file 1a. Abstracts
of recent meetings on infectious diseases were also included.
Serotype distribution data were extracted by five
reviewers for IPD, non-IPD and nasopharyngeal carriage.
In addition, data on Spn19A penicillin susceptibility,
pneumococcal disease prevalence and/or incidence,
mortality rate, and pneumococcal vaccine potential im-
pact were collected when available. For calculation of
impact using SIREVA data we assumed serotype 6A/6B
protection for PCV7 and PCV10 [4].
In order to avoid duplicate data, numbers were only
added from the databases of the SIREVA Project (only
for invasive isolates) available via the PAHO website,
[23]. Data included in the analysis: 2000–2005, 2006,
2007, 2008 and 2009, SIREVA corresponded to available
information in the original sources published according
to the methodology used for this systematic review.
We limited selection bias by reducing the heterogeneity
of samples; most data were from the SIREVA network for
invasive isolates with standardized laboratory surveillance
techniques and expanded availability of protocols. For the
inclusion and exclusion criteria used to select publications
reporting non IPD studies, we reviewed international cri-
teria and internationally defined and accepted sample col-
lection and laboratory techniques. For the purposes of this
systematic review, we adopted the definitions presented in
Additional file 1b.
We analyzed and presented our results following standard
guidelines. Prevalence estimates were computed using the
number of Spn19A isolates as the numerator and the total
number of S. pneumoniae reported as denominator, for each
study. Two techniques were used to calculate the pooled
prevalence estimates: Mantel-Haenszel (fixed-effects model)
and DerSimonian-Laird (random-effects model) [24,25].
For invasive disease meta-analysis we only included
publications reporting non- SIREVA data, considering that
SIREVA data represent 96.7% of samples analyzed and
would bias the pool estimation.
Lastly, we estimated Spn19A specific IPD incidence by
multiplying the serotype distribution by the reported
incidences identified in this review.
Results
Study selection
Our searches retrieved a total of 1704 references.
After reviewing the titles and abstracts, a total of 322
full texts were reviewed, 222 of which were excluded.
The final number of publications included was 100
and data were extracted from 63; the remaining 37
were referenced (Figure 1). The characteristics of the
63 studies reviewed and of those that were referenced
are described in Additional file 2.
The 63 references were divided into three categories:
studies with information on invasive serotypes (n = 14),
non-invasive isolates with individual information (n = 27)
and burden of disease or disease incidence studies
(n = 26). Four references provided information on more
than one of these categories.
Spn19A in IPD
Most of the IPD isolates identified came from the SIREVA
project (19084 of 19733; 96.7%) [23,26]. Of these 19733
isolates, 753 (3.8%) were Spn19A. There was no statisti-
cally significant difference in the prevalence of Spn19A
isolates between SIREVA (3.8%) and non-SIREVA (3.1%)
data (p= 0.3) (Tables 1 and 2).
When considering countries with more than 500 isolates
collected over a period of 17 years (1993–2009) or 10 years
(2000–2009) the total number of invasive isolates was
17831; 677 (3.9%) of these were Spn19A, ranging from
1.5% in Colombia to 7.0% in Venezuela (Table 1).
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Analysis of the prevalence of invasive serotypes data
from SIREVA (1993–2009) and non SIREVA data
(1989–2008) revealed that Spn19A ranked 9th in both
sets of data (3.8% SIREVA and 3.1% non-SIREVA (See
Additional file 3a)). In an analysis of the SIREVA data in
20 countries, Spn19A ranked 9th (3.6%) for the period
2000–2005, and 8th (4.6%) for the period 2006–2009
(See Additional files 3b and c).
The prevalence of Spn19A in the region, by country and
by time period is shown in Table 3. Spn19A accounted for
3.3% (CI95%: 1.8–4.9) of isolates between 1993 and 1999,
3.6% (CI95%: 2.3–4.9) between 2000 and 2005 and 4.6%
(CI95%: 3.4–5.8) between 2006 and 2009 (χ2 10.8, p
< 0.001). The prevalence of serotypes recorded from SIR-
EVA data collected during the three time periods pre-
sented by vaccine type (VT) (PCV7, PCV10, PCV13) and
non vaccine type (NVT), as well as Spn19A, prevalence by
region (SIREVA) (Average cases by study period (2000–
2005 vs. 2006 – 2009) is shown in Additional file 4. Ana-
lysis by SIREVA reports are presented in Figure 2.
We did not observe any statistical significant dif-
ferences in the prevalence of Spn19A isolates
reported between age groups (4.9% for <2 years vs.
5% for 2–5 years; p = 0.8), for the period 2007–2009
(See Additional file 5).
Spn19A was reported less frequently in meningitis cases
(3.0%) than in non-meningitis (4.6%; p< 0.01), with the ex-
ception of Paraguay (2.8%vs.2.0%). Differences were statis-
tically significant only for Brazil (3.0% vs. 4.8%; p =0.009)
(See Additional file 6a).
SIREVA data from the period 2006–2007 [23] showed
that pneumonia accounted for 59.4% of non-meningitis
cases (1069/1801) and 56% of all Spn19A (42/75). Overall,
Spn19A accounted for 3.9% of the pneumonia isolates in
LAC (See Additional file 6b). Data from 2000–2009,
showed that Spn19A was the 10th and 6th most frequently
reported serotype causing meningitis and non meningitis,
respectively (See Additional files 6c and d).
In non SIREVA data from studies in Argentina [27]
and Brazil [29], Spn19A accounted for 1.3% (2/152) of
meningitis and none of the 146 non-meningitis.
Spn19A in AOM
Data showing the frequency of serotype 19A amongst iso-
lates in cases of acute otitis media are presented in Table 4.
Despite representing more than 70% of the whole sample,
Figure 1 Flow diagram of the literature reviewed.
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only 0.6% of Costa Rican isolates were Spn19A. Data
grouped by VT (13, 10 and 7 valent vaccines) and NVT are
also shown (See Additional file 7a). Overall, Spn19A
accounted for 2.4% (11/460) of isolates, ranking the 9th
amongst the most frequent serotype for AOM.
Spn19A in nasopharyngeal carriage
Spn19A data from isolates in healthy children are shown
in Table 4; 20 serotypes were identified for 74.7% of
nasopharyngeal isolates, of which serotype 19F was the
most frequently reported (13.6 and Spn19A the 6th
(4.1%) (See Additional file 7b).
The distribution of Spn19A in healthy children (car-
riage) was similar from that seen for the smaller sample
of isolates collected from sick children (Table 4), where
Spn19A was the 5th most frequently reported serotype
(4.4% of total isolates) (See Additional file 7c).
S. pneumoniae susceptibility to penicillin. Serotype 19A
and other serotypes (2007–2009)
A total of 53.7% (22/41) of Spn19A isolates collected
from meningitis cases were reported to be resistant. For
non-meningitis isolates 10.8% of Spn19A isolates (17/
Table 2 Streptococcus pneumoniae serotype 19A, number







Argentina [27]a,b 1999–2002 0 0.0 153c
Brazil [28]b 1989–1993 2 4.1 49
Brazil [29]a 1995–1999 2 1.4 145
Chile [30]b 1994–2004 3 2.3 128
Chile [31]b 1995–1997 1 3.3 30
Mexico [32]b 1992–1993 11 9.2 120
Colombia [33]b 2008 1 4.2 20
Total 20 3.1 649
aMeningitis.
bUnspecified invasive disease.
ca = 7, b = 146.
Table 1 Streptococcus pneumoniae serotype 19A, number





Argentina 1993–2009 100 3.7 2692
Bolivia 2000–2009 5 3.1 160
Brazil 1993–2009 153 3.6 4262
CARECa 2000–2009 2 1.4 148
Chile 1993–2009 161 4.5 3617
Colombia 1993–2009 28 1.5 1819
Costa Rica 2000–2009 3 4.8 63
Cuba 2000–2009 31 3.4 899
DRb 2000–2009 14 2.6 544
Ecuador 2000–2009 5 2.3 215
El Salvador 2000–2009 5 9.6 52
Guatemala 2000–2009 11 9.3 118
Honduras 2000–2009 0 0.0 11
Mexico 1993–2009 91 6.2 1463
Nicaragua 2000–2009 2 4.7 43
Panama 2000–2009 15 7.7 194
Paraguay 2000–2009 17 2.2 784
Peru 2000–2009 8 3.2 249
Uruguay 1993–2009 44 3.6 1210
Venezuela 2000–2009 38 7.0 541
Total 733 3.8 19084
a CAREC: Caribbean Epidemiology Centre. b DR: Dominican Republic
References [23,26].
Number of invasive isolates by country. SIREVA data, 1993-2009.
Table 3 Streptococcus pneumoniae serotype 19A
prevalence in 20 countries, SIREVA data, 1993–2009
Country Periods analyzed [Reference]
1993–1999 [26] 2000–2005 [23,34] 2006–2009 [23]
19A Total 19A Total 19A Total
n % n % n %
Argentinaa 30 3.0 1006 33 3.5 936 37 4.9 750
Bolivia - - - 3 2.8 108 2 3.8 52
Brazil 42 3.5 1203 71 3.6 1963 40 3.6 1096
CARECb - - - 1 0.9 110 1 2.6 38
Chile 19 4.1 461 81 4.3 1894 61 4.8 1262
Colombiaa 4 0.6 623 6 0.9 647 18 3.3 549
Costa Rica - - - 0 0.0 3 3 5.0 60
Cuba - - - 28 3.3 842 3 5.3 57
DRc - - - 8 2.1 379 6 3.6 165
Ecuador - - - 0 0.0 55 5 3.1 160
El Salvador - - - 3 13.0 23 2 6.9 29
Guatemala - - - 4 4.4 91 7 25.9 27
Honduras - - - 0 0.0 3 0 0.0 8
Mexico 28 6.6 426 42 5.8 728 21 6.8 309
Nicaragua - - - 1 2.6 39 1 25.0 4
Panama - - - 7 6.9 101 8 8.6 93
Paraguay - - - 12 2.5 477 5 1.6 307
Peru - - - 3 2.1 143 5 4.7 106
Uruguay 13 3.7 352 18 3.1 575 13 4.6 283
Venezuela - - - 24 5.9 407 14 10.4 134
Total 136 3.3 4071 345 3.6 9524 252 4.6 5489
a Significant differences between 1993–1999 and 2006–2009 (Argentina
p = 0.03, Colombia p< 0.001).
b Caribbean Epidemiology Centre.
c Dominican Republic.
- No data available.
Prevalence in 20 countries. SIREVA data, 1993–2009.
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158) showed an intermediate level of resistance and 3.2%
(5/158), high resistance (Table 5) [61].
An analysis of other serotypes showed that among 453
resistant meningeal isolates, Spn19A was the 5th most
frequently reported serotype (4.9%) and that, for 248 re-
sistant non-meningitis isolates, it was 3rd (8.3%) (See
Additional file 8a). These data are presented by country
in Additional file 8b.
Spn19A meta-analysis
For invasive disease, our analysis of the data shows 1%
prevalence overall for this serotype, ranging from 0.03%
in Argentina to 9.2% in Mexico [27-33] (Figure 3a).
The prevalence of Spn19A in AOM was 0.8%, ranging
from 0.6% in Costa Rica to 16.7% in Mexico [35-37,39]
(Figure 3b).
The overall prevalence of Spn19A in healthy carriers,
for 9 different countries, was 2.5%, ranging from 0.4%
for studies conducted in Mexico between 2002 and 2003
period to 10.8% for studies conducted in Mexico in
2006, respectively [38-56] (Figure 3c). For sick children,
the overall prevalence for 4 countries was 2.7%, ranging
from 1.6% in Venezuela to 11.1% in Brazil [48,54,57-60]
(Figure 3d).
Spn19A burden of disease
Our literature search for publications on the burden of
disease caused by serotype 19A identified 26 papers;
Table 6 summarizes incidence rates reported. Incidences
by country are presented in Additional file 9.
Lagos et al. [46] monitored IPD related hospitaliza-
tions in Chile between 1994 and 2007. Among the sero-
types identified, “other” or “non-vaccine serotypes within
vaccine serogroups” (which included Spn19A) were
reported for 72 patients with invasive clinical syndromes.
For these patients, the case fatality rate was 0%. The
annual incidence of IPD among children 0–59 months
of age caused by Spn19A was 1 per 100,000.
In Córdoba, Argentina, Tregnaghi et al. [27] found a
highest incidence of IPD (206/100,000 children <2 years
old), attributed to ambulatory patients. No Spn19A iso-
lates were isolated.
Table 4 Streptococcus pneumoniae serotype 19A isolates
from acute otitis media and nasopharyngeal - healthy
and sick children





Brazil [35] 1990–1995 6 12.5 48
Colombia [36] 2008–2009 1 2.8 36
Costa Rica [37] 1992–2007 2 0.6 346
Mexico [38] 1995–2000 5 16.7 30
Total 11 2.4 460
Nasopharyngeal isolates - Healthy children
Argentina [39] 2000–2007 27 3.7 728
Brazil [40] 1998 1 0.7 135
Brazil [41] 2000 10 4.5 222
Brazil [42] 2000–2001 1 3.0 33
Brazil [43] 2005 21 6.3 332
Chile [44] 1994–1999 0 0.0 68
Chile [45] 1994–1995 5 10.0 50
Chile [46] 2001–2003 16 2.2 714
Colombia [47] 2009 6 3.5 170
Mexico [48] 1994 4 6.2 65
Mexico [38] 1997–2000 6 3.5 173
Mexico [49] 2002 50 6.0 829
Mexico [50] 2002–2003 0 0.0 122
Mexico [51] 2006 19 10.8 176
Panama [52] 2008 2 1.2 163
Peru [53] 2000 3 2.1 146
Uruguay [54] 1993–1995 3 4.1 74
Venezuela [55] 2004–2005 5 4.1 122
Venezuela [56] 2008 1 1.7 58
Total 180 4.1 4380
Nasopharyngeal isolates - Sick children
Brazil [57] 1997 3 1.9 162
Brazil [58] 2002–2003 1 8.3 12
Brazil [59] 2009 7 9.9 71
Mexico [48] 1994 5 7.2 69
Uruguay [54] 1993–1995 0 0.0 21
Venezuela [60] 2000 0 0.0 27
Total 16 4.4 362
Figure 2 Streptococcus pneumoniae serotype 19A distribution
of invasive isolates SIREVA data, 2000–2005, 2006, 2007, 2008,
2009.
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Pneumococcal vaccine potential impact for invasive disease
With the SIREVA data for IPD the estimated percentage
was 63% for PCV7, 79.3% for PCV10, and 85.5% for
PCV13. We carried out an analysis to establish the po-
tential benefit of adding Spn19A, 1 and 5. This showed
that addition of serotypes 1 and 5 increase impact by
13.2%, whilst addition of 19A increases vaccine impact
by 4% (see Additional file 10).
Discussion
This systematic review of Spn19A data in children under
6 years old, from studies conducted in LAC over a
period of 20 years shows that Spn19A remains a less
common agent of IPD than other serotypes (3.8%), rank-
ing 9th in the twenty most prevalent serotypes [23]. The
percentage of isolates accounted by Spn19A differed be-
tween countries, being the 10th most frequently reported
from Colombia, the 6th from Mexico and 4th from
Venezuela (Additional file 3a and Additional file 11).
This information provides a complete overview of the
role of Spn19A for pneumococcal disease facilitating the
decision process for those countries considering to
introduce PCV, but also will allow evaluation of poten-
tial variations in the prevalence of Spn19A and other
serotypes, as reported previously in studies following
introduction of PCV7 [14-19,23].
Our analysis of the literature identified the serotypes
accounting for 85.4% of IPD in the region, serotype 14
being the most common (28.7%). However, the percent-
age of isolates accounted for by each of these serotypes
varied from country to country, in agreement with
Johnson´s observation in her recent global serotype
paper [4].
The scope of our search strategy allowed us to retrieve
comprehensive lists of peer-reviewed publications. Two
of our authors being members of the SIREVA team, we
were able to identify the vast majority of relevant publi-
cations in non-indexed journals and obtain personal
communications with SIREVA coordinators [23]. Add-
itionally, information retrieved from over a 20 year
period evaluated secular trends and the periodicity of
serotypes described in the literature [1-4].
A strength of our analysis is that the percentage of
IPD Spn19A isolates reported in the non SIREVA data
that we reviewed (7 reports, 1990–2008) was not signifi-
cantly different from that for the SIREVA data (3.8%).
Regarding time period of Spn19A prevalence, a significant
increase, from 3.3% to 4.6%, was noted only in Argentina
and Colombia between 1994–1999 and 2006–2009 before
any universal vaccine intervention could have had an im-
pact. However, Spn19A stability was observed in Brazil,
Chile, Dominican Republic and Mexico. Similar increases in
the percentage of isolates accounted for Spn19A, even prior
to the introduction of PCV7, have been reported in Europe
[63], South Korea [64], Southern Israel [65] and Taiwan
[66], likely reflecting selection pressure from antibiotic use.
On the other hand, in the USA the observed increas-
ing prevalence of PRSP and MDR Spn19A has been sug-
gested to be due to a rapid expansion of the Spn19A
clonal complex CC320, to more than one new clone
introduced or to successful clones associated with other
serotypes that have undergone a recombinational switch
to Spn19A [20,21].
In the LAC region only one study, describing PFGE
patterns of Spn19A isolates, and conducted in Colombia
[67], reported Spn19A MDR isolates in IPD; two were
found related to the clone Colombia23F-ST338, one to
the clone Spain23F-ST81, and 6 were not related to the
clones studied. A possible explanation of these findings
may be that a successful clone, such as Spain23F, under-
went a recombinational switch to Spn19A.
No differences could be established between age
groups for the prevalence of Spn19A as an IPD agent. In
contrast, serotypes 1 and 5 were more frequent in chil-
dren 2–5 years old and serotypes 6B and 14 were more
frequent in <2 year olds than in the other age groups in
the LAC region (See Additional file 5).
Our analysis suggests that Spn19A causing IPD in
LAC is more frequently an agent of non-meningitis dis-
ease (4.5% of cases), in particular pneumonia than of
meningitis (2.9%) (See Additional file 6a).
PNSP in invasive Spn19A isolates has been reported in
LAC since 1993 [26]. A study conducted in 2010, using the
new CLSI breakpoints for penicillin [61], showed that re-
sistant Spn19A isolates are circulating in the region, more
frequently as agents of meningitis (MIC≥ 0.125 μg/ml)
than for of non-meningitis (MIC≥ 4.0 μg/ml). However,
Table 5 Streptococcus pneumoniae serotype 19A,









n % n % n %
2007 8 57.1 14 2c 5.1 0 0.0 39
2008 9 64.3 14 6 d 9.4 3 d 4.7 64
2009 5 38.5 13 9 e 16.4 2 e 3.6 55
Total 22 53.7 41 17 10.8 5 3.2 158
aCLSI 2010, Penicillin-Nonsusceptible S. pneumoniae (PNSP) resistant≥0.125 μg/ml [61].
bCLSI 2010, PNSP intermediate resistance (IR) = 4.0 μg/ml, PNSP high resistance
(HR)≥ 8.0 μg [61].
cBrazil (1) MIC 4.0 μg/ml (IR), Venezuela (1) MIC 4.0 μg/ml (IR).
dBrazil (2), MIC 4.0 μg/ml (IR); Venezuela (2), MIC 4.0 μg/ml (IR); Chile(1), MIC
4.0 μg/ml (IR); Mexico (1), MIC 4.0 μg/ml (IR); Peru (2), MIC ≥8.0 μg/ml (HR);
Colombia (1), MIC ≥8.0 (HR).
eChile (2), MIC 4.0 μg/ml (IR); Colombia (2), MIC 4.0 μg/ml (IR); Cuba (1), MIC
4.0 μg/ml (IR); Dominican Republic (1), MIC 4.0 μg/ml (IR); Mexico (5) 3 MIC
4.0 μg/ml (IR) and 2 MIC ≥8.0 μg/ml (HR).
Castañeda et al. BMC Infectious Diseases 2012, 12:124 Page 6 of 13
http://www.biomedcentral.com/1471-2334/12/124
the finding of a prevalence of 3.2% for Spn19A with
MIC≥ 8.0 μg/ml among non-meningitis cases, recovered
in Mexico, Colombia and Venezuela is of great concern, as
it follows reports of 7.7% of cases being attributed to sero-
type 19F. Molecular surveillance data will reveal their role
as agents of pneumococcal disease [20,21].
Despite the fact that S. pneumoniae causes 30–60% of
AOM cases worldwide [68], only three papers and one
abstract were found and analyzed; overall, 2.4% of these
were attributed to Spn19A. As AOM continues to be an
important childhood infection and given that the eti-
ology might change from VT to non-PCV7 strains once
pneumococcal vaccines are widely implemented [69], it
is important to conduct AOM etiology studies in the
region. S. pneumoniae may be subject to serotype re-
placement phenomena and attention to antibiotic resist-
ant NVT otopathogens as well as non typable
Haemophilus influenzae is required [70].
Nasopharyngeal carriage has been confirmed with
greater values reported for children less than 5 years old.
From the papers analyzed, Spn19A ranked the 6th most
frequently reported serotype for healthy children (4.1%),
jointly with Non-Typable. There were a high number of
serotypes with ability for colonizing the nasopharynx,
with serotype 19 F the most frequently identified (See
Additional file 7b).
Nasopharyngeal serotypes described in Latin America
from 1994 to 2008 are very similar to those described by
Figure 3 a Serotype 19A meta-analysis of invasive isolates. b Serotype 19A meta-analysis of AOM isolates. c Serotype 19A meta-analysis
healthy nasopharyngeal carriers. d Serotype 19A meta-analysis sick carriers.
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Huang in 2001 (pre vaccine data) for generally healthy chil-
dren in 16 Massachusetts communities. Spn19A repre-
sented 4.2% of 143 isolates; PNSP was described for 77% of
the NVT, in particular for serotypes 6A, 19A and 9A [12].
Studies conducted since the introduction of PCV7
vaccination have shown decreases in colonization with
pneumococcal VT shortly after immunization as well as
longer-term changes in colonization patterns. Huang
[12] reported a decrease in the carriage of VT from 36%
to 3% seven years after mass introduction of PCV7,
whereas NVT carriage increased from 15% to 29%. The
common colonizing serotypes in 2007 included 19A
(16%) (Baseline data 6.0%), 6A (12%), 15B/C (11%), 35B
(9%) and 11A (8%), a clear reflection of the replacement
phenomenon. Additionally, the more frequent coloniz-
ing serotypes have greater resistance to penicillin. Naso-
pharyngeal surveillance appears to be a reliable system
for measuring vaccination impact in terms of a decrease
in VT types and will help to elucidate the emergence of
NVT following PCV introduction.
Incidence rates reported by Lagos [46] for IPD caused
by Spn19A ranged from 0.4 to 2.2 cases x 100,000
between 1994 and 2007, suggesting a seasonal pattern
for this serotype. Similar variations have been shown for
other serotypes in the LAC region, such as 1 and 5 [34]
and may explain changes during time periods in the SIR-
EVA data presented in this review. This should be con-
sidered when interpreting data post introduction of
pneumococcal vaccines in this region. In contrast, the
incidence of other serotypes such as 14 has shown small
variations [26,34].
PCVs have been introduced recently in several coun-
tries in LAC, but currently, there are no data published
about their impact in reducing IPD. Consequently, little
is known about the replacement phenomenon with
Spn19A, which has been well described previously [22].
Available data provide only an estimation of hypothetical
impact (supplement 10). The same calculation for the
recent SIREVA data [4] showed a major impact of
PCV10 and PCV13 vaccination, in particular related to
the inclusion of serotypes 1 and 5. In fact, after 2009,
countries in the region have incorporated different PCV
into their expanded program of immunization following
individual assessment for their epidemiology (PCV7/13:
Costa Rica, Uruguay, Mexico and PCV-10: Brazil, Co-
lombia, Ecuador and Chile). Following the results of this
review, indicating the low prevalence of Spn19A in most
of the countries, it is necessary to report any subsequent
change in the distribution of this serotype in those coun-
tries who have introduced one of the available PCV. Par-
ticularly, trying to explain any increase or decrease in
the Spn19A prevalence comparing the statistics prior to
universal vaccination and possible factors that could ex-
plain this, such as vaccine coverage, antibiotic use and
immune response based on the vaccine formulation.
The results of our systematic review have a number of
limitations. The source of primary data, either from SIR-
EVA or from independent research teams, could introduce
selection bias, potentially promoting the selection of more
severe forms of the disease. However, it is important to
highlight that more severe disease will have the largest im-
pact from a burden of disease or a public health perspec-
tive. Information on disease severity caused by Spn19A in
this region was limited; this is also the case for data col-
lected for other serotypes, given that similar surveillance ac-
tivities are employed in the different countries. As this
limitation is not restricted to a specific serotype, it should
not bias our conclusions. It was not possible to analyze
temporal changes in serotype frequency, except from a very
broad perspective. The small amount of data available on
burden of disease and on the possible effects of mass vac-
cination highlights the need for more research in this area.
Incidence of IPD in this region ranges from 3.0 to
206.8 cases per 100,000. Overall 9 serotypes are respon-
sible for 80% of IPD and 30% are due to serotype 14;
Spn19A remains relatively uncommon as an agent of
Table 6 Estimates of the incidence rate of different
pneumococcal diseases in Latin America and the
Caribbean and S. pneumoniae 19A specific incidence
Range expressed in cases per 100,000/year
Condition Age group (years)




61 (58–63)a 61 (52–71) 32 (32–33)
S. pneumoniae 19A
specific incidenceb
2.3 (2.2–2.9) 2.8 (2.4–3.3)
Pneumococcal
meningitis
19 12 11 (9–15)
S. pneumoniae 19A
specific incidencec

















(Adapted from reference [62]).
a (25th–75th percentile, when reported).
b S. pneumoniae 19A distribution reported in SIREVA 1993–2009 = 3.8%.
c S. pneumoniae 19A distribution reported in SIREVA 2000–2009 = 3.0%.
d S. pneumoniae 19A distribution reported in SIREVA 2006–2007 = 3.9%.
e S. pneumoniae 19A distribution reported in SIREVA 2000–2009 = 4.6%.
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IPD, with the exception of Mexico and Venezuela. Data
on noninvasive disease and nasopharyngeal carriage, al-
though not as robust, show the same low prevalence.
Conclusions
As several countries in the region implemented PCV in their
routine schedules starting in 2006, regional data on vaccin-
ation impact on IPD, non invasive and nasopharyngeal car-
riage by VT and herd effect should soon be available. In the
near future we expect that data on VT and NVT, supported
by a solid surveillance system, will be available, which will
support public health decisions on the introduction of PCV.
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